SynthesisEpidemics2021
Mathematical modelling of respiratory syncytial virus (RSV) in low- and middle-income countries: A systematic review.
Synthesis in Epidemics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Cost of childhood RSV management and cost-effectiveness of RSV interventions: a systematic review from a low- and middle-income country perspective.BMC medicine · 2023Pooled it
- Disease burden estimates in economic evaluation studies of Respiratory Syncytial Virus (RSV) maternal immunization: a systematic review protocol.Systematic reviews · 2026Article
- Integrated pharmaceutical and behavioral strategies for long-term control of RSV transmission: An impulsive SEIRS-type modeling study.AIMS public health · 2026Article
- Respiratory syncytial virus (RSV) infections in adults: Current trends and recommendations for prevention - a global challenge from a local perspective.Human vaccines & immunotherapeutics · 2025Review
- Community participatory approaches in infectious disease dynamic transmission modelling: a scoping review protocol.BMJ open · 2025Article
- Respiratory syncytial virus hospitalization costs, rates, and seasonality in Asia: a systematic review and meta-analysis.EClinicalMedicine · 2025Review
- Time trends in the burden of non-COVID-19 lower respiratory tract infections among children aged 0 to 14 years.Frontiers in cellular and infection microbiology · 2025Article
- Maternal vaccination against RSV can substantially reduce childhood mortality in low-income and middle-income countries: A mathematical modeling study.Vaccine: X · 2023Article
- Article
- The Ability of Postimmunobiotics fromMicroorganisms · 2022Article
- Determinants of RSV epidemiology following suppression through pandemic contact restrictions.Epidemics · 2022Article
- A Multivariate Age-Structured Stochastic Model with Immunization Strategies to Describe Bronchiolitis Dynamics.International journal of environmental research and public health · 2021Article
- Models of Epidemiological Security Management in the Spread of the SARS-CoV-2 Virus.IFAC-PapersOnLine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundDue to high burden of respiratory syncytial virus (RSV) in low- and middle-income countries (LMIC), international funding organizations have prioritized the development of RSV vaccines. Mathematical models of RSV will play an important role in assessing the relative value of these interventions. Our objectives were to provide an overview of the existing RSV modelling literature in LMIC and summarize available results on population-level effectiveness and cost-effectiveness.
methodsWe searched MEDLINE from 2000 to 2020 for English language publications that employed a mathematical model of RSV calibrated to LMIC. Qualitative data were extracted on study and model characteristics. Quantitative data were collected on key model input assumptions and base case effectiveness and cost-effectiveness estimates for various immunization strategies.
findingsOf the 283 articles reviewed, 15 met inclusion criteria. Ten studies used modelling techniques to explore RSV transmission and/or natural history, while eight studies evaluated RSV vaccines and/or monoclonal antibodies, three of which included cost-effectiveness analyses. Six studies employed deterministic compartmental models, five studies employed individual transmission models, and four studies used different types of cohort models. Nearly every model was calibrated to at least one middle-income country, while four were calibrated to low-income countries.
interpretationThe mathematical modelling literature in LMIC has demonstrated the potential effectiveness of RSV vaccines and monoclonal antibodies. This review has demonstrated the importance of accounting for seasonality, social contact rates, immunity from prior infection and maternal antibody transfer. Future models should consider incorporating individual-level risk factors, subtype-specific effects, long-term sequelae of RSV infections, and out-of-hospital mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.